Every article, presentation, spotlight, and news item we've tagged to Genetics & Epigenetics.
Methylation controls over one billion cellular reactions per second, affecting everything from energy to mood to aging. Understanding your unique methylation genetics could be the missing piece in your optimization journey.
Your cells might be aging faster than your calendar. New epigenetic tests decode DNA methylation patterns across 900,000+ markers to reveal your true biological age—even pinpointing which organs age fastest.
Discover how epigenetic testing reveals your true biological age versus chronological age with Ryan Smith, founder of TruDiagnostic. Learn how DNA methylation patterns can predict health outcomes with 92% accuracy and track the effectiveness of longevity interventions in real-time. Smith reveals how aging is the #1 risk factor for chronic disease—10x more significant than smoking or obesity—and demonstrates how epigenetic clocks can measure biological aging from a single drop of blood, providing over 100 biomarkers to optimize your health span.
APOE2, a genetic variant associated with exceptional longevity, activates DNA repair pathways and resists cellular senescence in neurons, while APOE4 exhibits elevated DNA damage and senescence markers. This mechanism extends beyond lipid metabolism, explaining APOE2's protective effects against neurodegeneration.
APOE4, a major Alzheimer's disease risk gene, compromises bone quality in women through disruption of osteocytes—the long-lived cells responsible for maintaining bone microarchitecture—despite normal appearance on standard imaging. This finding suggests bone deterioration may serve as an early, detectable signal of neurodegenerative risk before cognitive symptoms emerge.
APOE4 carriers exhibit elevated neuronal excitability in specific hippocampal regions during youth, before cognitive symptoms manifest, with early excitability patterns predictive of later cognitive decline. This mechanism resembles accelerated aging and offers a window for intervention before irreversible neurodegeneration.
Roche has obtained CE mark approval for a blood test that identifies ApoE4 carriers, a genetic variant associated with increased Alzheimer's risk. This test streamlines risk stratification and treatment planning by enabling clinicians to prioritize patients for further evaluation and guide therapeutic decisions, particularly regarding amyloid-targeting therapies that carry differential risk profiles based on ApoE4 status.
Scribe Therapeutics and Eli Lilly have achieved a second milestone in developing in vivo CRISPR-based therapies for neurological and neuromuscular diseases. This advances the practical application of gene editing directly within the body, potentially enabling durable treatments delivered once or rarely, rather than requiring repeated interventions over a patient's lifetime.
Unlimited Bio has initiated a Phase 1/2a clinical trial combining AAV9-Follistatin and VEGF plasmid gene therapy to address age-related muscle loss and vascular insufficiency. The dual approach targets both muscle growth capacity and the circulatory support system that sustains muscle function—a systems-level intervention designed to address interconnected aspects of aging.
A 15-year Swedish cohort study found that unprocessed meat consumption was associated with preserved cognitive trajectory and reduced dementia risk in APOE ε4 carriers, effectively neutralizing the genotype's established cognitive penalty at higher intake levels. This finding challenges the assumption that ε4 carriers universally benefit from plant-forward diets and suggests ancestral dietary patterns may interact with genetic risk architecture in ways that modern nutritional guidelines do not account for.
Physical fitness metrics correlate with DNA methylation patterns of circulating proteins, revealing molecular pathways that link muscular strength, aerobic capacity, body composition, and cognitive function to reduced risk of age-related diseases. This molecular mapping enables patient-level disease risk stratification based on combined fitness and epigenetic measurements.
Young mice carrying the APOE4 gene variant show excessive electrical activity in the hippocampus before cognitive decline becomes apparent, a pattern driven by neuronal APOE4 expression itself. This early hyperexcitability represents a tractable target for intervention, as it can be reversed through modulation of the Nell2 pathway.
Scribe Therapeutics is advancing engineered CRISPR platforms, including STX-1150, a liver-targeted epigenetic therapy that achieves sustained LDL-C reduction from a single dose without permanent genomic modification. The technology demonstrates enhanced specificity and potency in cardiometabolic applications, positioning epigenetic approaches as a precision intervention for cardiovascular risk factors.
Multiple biotech companies are developing cell-based therapies targeting aging as an underlying condition rather than treating age-related diseases individually. The longevity biotech market is projected to grow from $9.86 billion in 2025 to $29.7 billion by 2034, driven by approaches using encapsulated cells, gene therapy, and stem cell platforms.
A comprehensive market analysis catalogs over 80 RNA therapy companies and 100+ drug candidates across multiple modalities—mRNA, siRNA, antisense oligonucleotides, aptamers, and CRISPR approaches. The research examines development stages, delivery mechanisms, and commercial landscapes, with established players like Novartis and Arrowhead Pharmaceuticals advancing candidates across multiple therapeutic areas.
Unlimited Bio initiated a Phase 1/2a trial combining AAV9-Follistatin and VEGF plasmid gene therapies to address age-related muscle decline, marking the first registered clinical study to combine these two approaches. The dual-therapy strategy targets both muscle growth signaling and vascular support, with safety and functional outcomes tracked over 12 months in adults aged 45 to 75.
Telocyte's founder argues that effective longevity intervention requires reversing aging at the cellular level rather than managing age-related diseases incrementally. The company is preparing a telomerase gene therapy trial in dogs, with the thesis that aging results from failed maintenance systems that can be reset rather than from inevitable biological decline.
VectorY Therapeutics has dosed the first patient in a Phase 1/2 trial of VTx-002, a gene therapy designed to sustain antibody production against pathological TDP-43 protein in ALS. This represents a shift from symptomatic management toward addressing the underlying biology of neurodegeneration, with implications for protein aggregation disorders across aging.
Flagship Pioneering launched Serif Biomedicines to develop Modified DNA medicines—a hybrid platform combining DNA and mRNA delivery with reduced immune activation and enhanced durability. The approach targets rare genetic diseases and immune reprogramming with preclinical evidence of tolerability and sustained gene expression in primates.
GADD45B deletion induces DNA methylation patterns resembling age-associated changes in hematopoietic stem cells, yet these methylation alterations occur without functional decline. The research distinguishes between methylation signatures and actual loss of HSC capacity, providing a resource to identify which methylation sites causally drive age-related hematopoietic dysfunction.
Rafael Holdings secured exclusive MIT patent rights for cyclodextrin-based molecules targeting ApoE4-positive Alzheimer's disease by restoring cholesterol transport between brain cells. This represents a shift from amyloid-clearance paradigms toward addressing the cellular infrastructure that prevents pathological buildup in the first place.
Gordian Bio describes a scalable in-vivo mosaic screening platform that uses barcoded CRISPR libraries and single-cell readouts to establish causal gene-disease relationships in living organisms. This approach accelerates therapeutic target discovery by testing multiple genetic perturbations simultaneously, reducing experimental variation and improving efficiency compared to traditional methods.
The cell and gene therapy market demonstrates commercial maturation with Zolgensma generating $1.2 billion and Yescarta $1.5 billion in annual sales, reflecting regulatory acceptance of 46 FDA-approved CGT products. This market trajectory indicates that genetic and cellular interventions are transitioning from experimental to established therapeutic options for previously intractable genetic disorders and certain cancers.
GenSight Biologics secured €1.7 million in funding to advance gene therapy programs targeting inherited retinal and mitochondrial diseases, with lead support from existing shareholders Advent France Biotechnology and RA Capital Management. The capital will fund clinical development of GS010/LUMEVOQ for Leber hereditary optic neuropathy and operational milestones through 2026.
AIRNA has initiated Phase 1 testing of AIR-001, an RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD), a genetic condition causing progressive lung and liver damage. Unlike permanent gene editing, RNA editing allows for repeated dosing and adjustment, positioning the approach as a reversible, titratable intervention aligned with how chronic disease and aging actually progress.
Life Biosciences secured $80 million to advance ER-100, the first partial epigenetic reprogramming therapy entering human trials, designed to restore cellular function in age-damaged neurons. This represents a shift in aging intervention from symptom management toward addressing the underlying cellular decline that drives multiple age-related diseases.
Circulating small RNAs, particularly nine piRNAs, predict two-year survival in older adults with greater accuracy than age and clinical factors alone, with experimental evidence suggesting reduced piRNA levels associate with extended lifespan. These findings identify specific small RNA signatures as measurable biomarkers and potential therapeutic targets for longevity interventions.
